In:
Breast Cancer Management, Future Medicine Ltd, Vol. 8, No. 1 ( 2019-03), p. BMT22-
Abstract:
Aim: To prospectively assess the impact of gene expression-based assay Breast Cancer Index (BCI) on extended endocrine therapy (EET) decision-making. Patients & methods: The BCI-tested samples from primary tumors (Stage I–III, hormone receptor positive breast cancer, 〉 3.5 year endocrine therapy). Patients and physicians completed questionnaires on EET preferences and decision conflict. Using these data, a fact-based economic model was developed to project the cost impact of BCI. Results: The BCI results affected treatment recommendations for 42/141 patients (overall mean, 62 year; 83% postmenopausal; 63% Stage I). Patient decision conflict decreased pre- to post-test. The BCI-related projected net savings (US$5190/patient) was robust under sensitivity analysis. Conclusion: Incorporating BCI into clinical practice meaningfully impacted physician EET recommendations and decreased patient decision conflict, with projected cost savings.
Type of Medium:
Online Resource
ISSN:
1758-1923
,
1758-1931
DOI:
10.2217/bmt-2019-0001
Language:
English
Publisher:
Future Medicine Ltd
Publication Date:
2019
detail.hit.zdb_id:
2669704-X
Permalink